Centrum Alergologii Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases
The clinic conducts research on immune-mediated allergic conditions, aiming to test new allergen immunotherapy approaches and biologic treatments to relieve symptoms and enhance long‑term control.
- Birch pollen allergen immunotherapy efficacy
- Grass pollen immunotherapy in pediatric patients
- Biologic therapy for chronic spontaneous urticaria
Centrum Alergologii Sp. z o.o. leverages its specialist allergy clinic to bring innovative therapies to patients in Lublin.
Respiratory Tract Diseases
Research focuses on recurrent respiratory infections in young children, evaluating oral bacterial lysate to lower the frequency of wheezing episodes and improve overall respiratory health.
- Recurrent RTIs in children aged 6 months to 5 years
- Wheezing lower respiratory illness management
- Effect of immunomodulatory therapy on asthma comorbidity
The Lublin‑based center collaborates with local pediatric practices to enroll participants and monitor outcomes.
Skin and Connective Tissue Diseases
The site investigates chronic spontaneous urticaria, comparing a biosimilar agent with an established anti‑IgE therapy to determine therapeutic equivalence and safety.
- Management of antihistamine‑resistant urticaria
- Biosimilar versus reference biologic efficacy
- Patient‑reported outcome improvements
Through its dedicated allergy clinic, the center seeks to enhance quality of life for patients suffering from persistent skin reactions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 52 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Alergologii Sp. z o.o.
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 52 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Glycopyrronium Bromide | 2 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.